Yeon Seung Chung

Yeon Seung Chung

Auto-generated profile, based on publicly available information

Yeon Seung Chung

Department of Pathology, Severance Hospital Yonsei University College of Medicine Seoul South Korea

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in Lung Cancer
Verified
Journal Article
Closed access
MKMoonsik Kim
Moonsik Kim
YCYeon Seung Chung
Yeon Seung Chung
KKKyoung A Kim
Kyoung A Kim
HSHyo Sup Shim
Hyo Sup Shim

15 July 2019 in Journal of Pathology and Translational Medicine
Verified
Journal Article
Open access
PDF file
HKHyun-Soo Kim
Hyun-Soo Kim
YCYeon Seung Chung
Yeon Seung Chung
MKMoonsik Kim
Moonsik Kim
HRHYANG JOO RYU
HYANG JOO RYU
JLJi Hee Lee
Ji Hee Lee

27 August 2025 in Clinical and Translational Medicine
Verified
Journal Article
Open access
JWJeongsoo Won
Jeongsoo Won
YCYeon Seung Chung
Yeon Seung Chung
SJSe-Young Jo
Se-Young Jo
JPJiho Park
Jiho Park
HSHyo Sup Shim
Hyo Sup Shim
SKSangwoo Kim
Sangwoo Kim
•MeTel is a novel Bayesian algorithm that accurately classifies multifocal lung cancers.

10 June 2022 in Research Square
Verified
Preprint
Open access
PDF file
YCYeon Seung Chung
Yeon Seung Chung
YJYoungsic Jeon
Youngsic Jeon
JYJeong Eun Yoo
Jeong Eun Yoo
TCTaek Chung
Taek Chung
HRHyungjin Rhee
Hyungjin Rhee
YPYoung Nyun Park
Young Nyun Park
Background: The differential diagnosis of intrahepatic cholangiocarcinomas (iCCAs) from metastatic adenocarcinomas from organs adjacent to the liver is difficult due to histopathological similarity and a lack of specific markers. This study evaluates the performance of albumin mRNA in situ hybridization (ISH) and immunohistochemistry (IHC) of filamin-A and cytokeratin 19 (CK19) for differential diagnosis.Methods: A total of 181 iCCAs and 116 adenocarcinomas from extrahepatic organs (30 gallbladder, 28 pancreas, and 58 stomach) were collected, and albumin ISH and IHC for filamin-A and CK19 were performed. The sensitivity, specificity, and the area under the curve (AUC) on the receiver operating characteristic (ROC) curve analysis of each marker were evaluated for the diagnosis of iCCA over extrahepatic adenocarcinoma.Results: Albumin ISH showed 23.2% sensitivity and 100% specificity for iCCAs, including both the small-duct and large-duct types. The expression of filamin-A and CK19 in albumin ISH-negative iCCAs was compared with that in extrahepatic adenocarcinomas. Filamin-A showed 71.1% sensitivity, 87.5% specificity, and 0.79 AUC on the ROC in small-duct-type iCCAs, whereas it had 27.5% sensitivity, 87.5% specificity, and 0.58 AUC on the ROC in large-duct-type iCCAs. CK19 showed 87.9% sensitivity, 59.4% specificity, and 0.74 AUC on the ROC in large-duct-type iCCAs, whereas it had 44.7% sensitivity, 59.4% specificity, and 0.52 AUC on the ROC in small-duct-type iCCAs.Conclusion: Albumin ISH and IHC for filamin-A and CK19 showed distinct expression patterns according to iCCA type. Albumin ISH positivity supports the possibility of iCCA, and filamin-A IHC is helpful for differentiating small-duct-type iCCA from extrahepatic adenocarcinomas.